Despite the setback, analysts view the correction as a buying opportunity, citing the company’s strong order book of ₹11,900 crore and robust long-term growth prospects.
Nifty’s Pharma and Healthcare indices have gained 1.7% and 2.6% respectively in the past month, while the benchmark Nifty declined 2% in this period.
The lawsuit filed in US District Court in Columbus, Ohio, claims the Fed’s practice of determining how big banks perform against hypothetical economic turmoil, and
Advertiser Disclosure
Great-investor.com helps users across the globe to find out The latest news, Guides, and Info about finance and investments. Furthermore, our content and research teams do not participate in any advertising planning nor are they permitted access to advertising campaign data.
Disclaimer
It is our organization’s primary mission to provide reviews, commentary, and analysis that are unbiased and objective. While great-investor.com has some data verified by industry participants, it can vary from time to time. Operating as an online business, this site may be compensated through third party advertisers. Our receipt of such compensation shall not be construed as an endorsement or recommendation by great-investor.com, nor shall it bias our reviews, analysis, and opinions. Please see our General Disclaimers for more information
Top10 International FZ LLE | 17th Floor, Creative Tower | 4422 | Fujairah | TRN: 100608946800003